Biogen Stock News

Biogen: All About Aduhelm Again In 2022, But Expecting Upside

Biogen (NASDAQ:BIIB) had its target price reduced by equities research analysts at Bank of America from $295.00 to $275.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a neutral rating on the biotechnology companys stock. Bank of Americas price target indicates a potential upside of 17.28% from the companys previous []

Biogen Inc. (NASDAQ:BIIB) – Equities researchers at William Blair lifted their Q4 2021 EPS estimates for Biogen in a research note issued to investors on Monday, December 20th. William Blair analyst M. Minter now anticipates that the biotechnology company will post earnings of $3.56 per share for the quarter, up from their prior forecast of […]

Can Biogen pull itself back from the brink in 2022?

Biogen (NASDAQ:BIIB) had its price objective dropped by equities research analysts at Robert W. Baird from $296.00 to $258.00 in a research note issued to investors on Tuesday, Price Targets.com reports. The firm currently has a neutral rating on the biotechnology companys stock. Robert W. Bairds price target would indicate a potential upside of 10.03% [] The post Robert W. Baird Lowers Biogen (NASDAQ:BIIB) Price Target to $258.00 appeared first on ETF Daily News .

Biogen Inc. (BIIB) closed the most recent trading day at $234.48, moving -0.07% from the previous trading session.

Biogen has been one of the biggest U.S. blue-chip losers since June, mostly on troubles launching its first-to-market Alzheimer's drug.

CAMBRIDGE, Mass., Dec. 22, 2021Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the First Committee on New Drugs (NDC) of the Pharmaceutical Affairs and Food Sanitation C

Save(0) Please login to bookmark Username or Email Address Password Remember Me Swiss pharmaceutical company Biogen has won discovery of documents sent from Sandoz to [] Subscribe for instant access to all Lawyerly content. Already a subscriber? Username or Email Address Password Remember Me Lost your password? Want to test drive Lawyerly? Contact us to take a free trial. The post Biogen wins discovery for potential IP lawsuit against Sandoz appeared first on Lawyerly .

An advisory panel to the Japanese drug regulator is continuing deliberations on the new drug application filed by Biogen Inc. BIIB, -0.97% and partner Eisai Co. Ltd ESALY, +0.69% 4523, +1.21% , the co

Biogen (NASDAQ:BIIB) had its price target lowered by investment analysts at SVB Leerink from $450.00 to $325.00 in a research note issued on Monday, Price Targets.com reports. The firm currently has an outperform rating on the biotechnology companys stock. SVB Leerinks price target would indicate a potential upside of 38.50% from the companys previous close. []